Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2660942 | 0.96 | MAPK1 (0.35) | CNR1GRM5CRHR1ACHEHTR2A | |
| SCHEMBL2656669 | 0.88 | GABRG2 (0.41) | CNR1CRHR1MAPTHTR2AHTR2C | |
| SCHEMBL2658404 | 0.84 | GABRG2 (0.39) | CNR1POLB | |
| SCHEMBL2661253 | 0.84 | NPY1R (0.40) | CNR1CRHR1HTR2AHTR2CKDM4E | |
| SCHEMBL2660877 | 0.82 | MAPK1 (0.43) | GRM5MAPTKDM4EPOLBPARP1 | |
| SCHEMBL2661112 | 0.82 | BMPR1A (0.32) | CNR1GRM5CRHR1ACHEMAPT | |
| SCHEMBL2656099 | 0.81 | PARP1 (0.35) | GRM5MAPTPOLBPARP1HTT | |
| SCHEMBL4920996 | 0.80 | MAPK1 (0.37) | GRM5MAPTPOLBPARP1HTT | |
| SCHEMBL2660594 | 0.80 | NPY1R (0.38) | ACHEMAPTPOLB | |
| SCHEMBL2669396 | 0.80 | PARP1 (0.35) | GRM5POLBPARP1HTTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | claimed |
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318943-A1 | Compounds and Uses Thereof - 848 | COMT, BACE1, BDNF | CNR1 443/4885GRM5 222/4885CRHR1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.